Boston Scientific (BSX) to Release Quarterly Earnings on Wednesday

Boston Scientific (NYSE:BSXGet Rating) will be announcing its earnings results before the market opens on Wednesday, February 1st. Analysts expect the company to announce earnings of $0.47 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Boston Scientific (NYSE:BSXGet Rating) last announced its earnings results on Wednesday, October 26th. The medical equipment provider reported $0.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.01). The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Boston Scientific had a return on equity of 14.55% and a net margin of 5.19%. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.41 EPS. On average, analysts expect Boston Scientific to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Boston Scientific Trading Down 0.0 %

Shares of Boston Scientific stock opened at $45.84 on Wednesday. The stock has a market capitalization of $65.66 billion, a P/E ratio of 109.15, a price-to-earnings-growth ratio of 2.30 and a beta of 0.83. The company has a quick ratio of 0.95, a current ratio of 1.45 and a debt-to-equity ratio of 0.49. The company has a 50-day simple moving average of $45.56 and a 200 day simple moving average of $42.39. Boston Scientific has a 12-month low of $34.98 and a 12-month high of $47.95.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on BSX shares. StockNews.com initiated coverage on shares of Boston Scientific in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Barclays raised their price objective on shares of Boston Scientific from $49.00 to $53.00 in a research report on Wednesday, January 4th. Raymond James raised their price objective on shares of Boston Scientific from $48.00 to $54.00 in a research report on Thursday, December 8th. Truist Financial raised their price objective on shares of Boston Scientific from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, December 20th. Finally, Mizuho initiated coverage on shares of Boston Scientific in a research report on Thursday, December 22nd. They issued a “neutral” rating and a $52.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

Insider Buying and Selling at Boston Scientific

In other news, EVP Wendy Carruthers sold 1,678 shares of the business’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $42.60, for a total value of $71,482.80. Following the completion of the sale, the executive vice president now owns 94,913 shares of the company’s stock, valued at $4,043,293.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Wendy Carruthers sold 1,678 shares of the company’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $42.60, for a total transaction of $71,482.80. Following the completion of the sale, the executive vice president now owns 94,913 shares of the company’s stock, valued at $4,043,293.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney sold 125,827 shares of the company’s stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $41.97, for a total transaction of $5,280,959.19. Following the sale, the chief executive officer now directly owns 1,767,665 shares of the company’s stock, valued at approximately $74,188,900.05. The disclosure for this sale can be found here. Insiders have sold a total of 220,265 shares of company stock worth $9,561,634 over the last ninety days. Insiders own 0.66% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Institutional investors and hedge funds have recently bought and sold shares of the company. Centiva Capital LP bought a new stake in Boston Scientific during the second quarter worth about $395,000. Graham Capital Management L.P. bought a new position in shares of Boston Scientific in the first quarter worth about $385,000. CENTRAL TRUST Co lifted its holdings in shares of Boston Scientific by 3.6% in the third quarter. CENTRAL TRUST Co now owns 8,862 shares of the medical equipment provider’s stock worth $343,000 after acquiring an additional 310 shares during the last quarter. Golden State Equity Partners bought a new position in shares of Boston Scientific in the first quarter worth about $333,000. Finally, XTX Topco Ltd bought a new position in shares of Boston Scientific in the first quarter worth about $309,000. Institutional investors own 90.23% of the company’s stock.

About Boston Scientific

(Get Rating)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

Featured Articles

Earnings History for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.